Abivax is mobilizing the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer.
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Abivax leverages three technology platforms for drug discovery:
Modulation of RNA Biogenesis: ABX464
Immune Enhancement: ABX196
Polyclonal Antibody: ABX544
In addition, Abivax is advancing multiple preclinical candidates for the treatment of additional viral infections such as Respiratory Syncytial Virus (RSV), Dengue, and Influenza from its Modulation of RNA Biogenesis platform and several of these compounds could enter clinical development before 2021.
Abivax’s most advanced compound, ABX464, has completed a Phase 2a clinical trial studying its potent anti-inflammatory effect and its potential ability to treat ulcerative colitis. Following the positive results from this trial, Abivax is advancing ABX464 into Phase 2b clinical trials in ulcerative colitis as well as Phase 2a clinical trials in Crohn’s disease and rheumatoid arthritis in the first quarter of 2019.
ABX464 has also completed two Phase 2a clinical trials studying its ability to reduce viral reservoirs in patients with HIV. This reduction is necessary for any viable cure of HIV, and Abivax is striving to develop this candidate to fill this unmet need. The Phase 2b program is expected to start in the first half of 2019.